Evidence map›Paper›PMID 36271156›Full record

ArticleActa pharmacologica Sinica2023

Comparison of two methods for tumour-targeting peptide modification of liposomes.

Shi-Qi Huang, Han-Ming Zhang, Yi-Cong Zhang, Lu-Yao Wang, Zhi-Rong Zhang, Ling Zhang

Open access · greenAbstract read
In one paragraph

Article in Acta pharmacologica Sinica, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Shi-Qi HuangKey Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy; College of Polymer Science and Engineering; Med-X Center for Materials, Sichuan University, Chengdu, 610041, China.
Han-Ming ZhangKey Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy; College of Polymer Science and Engineering; Med-X Center for Materials, Sichuan University, Chengdu, 610041, China.
Yi-Cong ZhangKey Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy; College of Polymer Science and Engineering; Med-X Center for Materials, Sichuan University, Chengdu, 610041, China.
Lu-Yao WangKey Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy; College of Polymer Science and Engineering; Med-X Center for Materials, Sichuan University, Chengdu, 610041, China.
Zhi-Rong ZhangKey Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy; College of Polymer Science and Engineering; Med-X Center for Materials, Sichuan University, Chengdu, 610041, China.
Ling ZhangKey Laboratory of Drug Targeting and Drug Delivery Systems, Ministry of Education, West China School of Pharmacy; College of Polymer Science and Engineering; Med-X Center for Materials, Sichuan University, Chengdu, 610041, China. zhangling83@scu.edu.cn.
Ministry of Education of the People's Republic of China · CNSichuan Research Center of New Materials · CNSichuan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Liposomes decorated with tumour-targeting cell-penetrating peptides can enhance specific drug delivery at the tumour site. The TR peptide, c(RGDfK)-AGYLLGHINLHHLAHL(Aib)HHIL, is pH-sensitive and actively targets tumour cells that overexpress integrin receptor α

Indexed as

LiposomesNeoplasmsAnimalsCell Line, TumorDrug Delivery SystemsMicePaclitaxelPeptidesTumor MicroenvironmentLiposomesPaclitaxelPeptidesB16F10 melanoma cellsC18-TRcell-penetrating peptidesliposomesTRtumour-targeting

Identifiers

PMID36271156
PMCPMC10043035
OpenAlexW4306973574

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.